Acutaas ChemicalQ2 FY25

Acutaas Chemical Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,942.9P/E: 73.5Market Cap: ₹32.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 2
  • AMI Organics targets a 30% revenue growth for FY25, revised upward from 25%, driven by strong order book and forecast.
  • The company expects a consistent ~25% CAGR growth in the medium term based on a robust product pipeline and existing CDMO contracts.
  • CDMO business to scale up materially from Q3 FY25 onwards, providing sizable additional revenue.
  • Ankleshwar unit at full utilization is expected to generate around ₹900 crore revenue, with 310 crore CAPEX invested.
  • The ramp-up for the Fermion contract and CDMO projects will continue through FY25, with full capacity utilization expected by FY26.
  • Specialty Chemicals (excluding Baba Fine Chem) is growing over 25%, and pharma intermediates grew 53% Y-o-Y in Q2 FY25.
  • New geographic expansions (e.g., Korea, Japan) and product launches support growth beyond FY25.
  • EBITDA margins expected to improve on operational leverage and stabilized pricing through FY25-FY26.

See what Acutaas Chemical management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • No explicit mention of any new fundraising through debt or equity at present or in the near future.
  • The company has recently completed a QIP (Qualified Institutional Placement) raising around Rs. 500 crore, used mainly for debt repayment (~Rs. 250 crore) and CAPEX.
  • Current cash and cash equivalents stand at Rs. 279 crore.
  • No mention of plans for further QIP or debt raising during FY25 or FY26.
  • CAPEX guidance for FY25 is Rs. 250 crore and FY26 is Rs. 40 crore, expected to be funded through internal accruals and existing resources.
  • Management highlighted cautious investment approach, especially regarding the EV-related JV, waiting for clear visibility before committing funds.

See what Acutaas Chemical management said on order book — free account, 30 seconds.

Capex plans

Yes
  • FY25 CAPEX for AMI Organics is around ₹250 crore, including:
  • - ₹70 crore for Unit 2 Ankleshwar site (expected completion Q3 FY25)
  • - ₹100 crore for electrolyte additive project (capacity 2000 MT for VC and FEC, completion expected by Q1 FY26)
  • - ₹60 crore for captive solar power plant (completion expected by end Q3 FY25)
  • - ₹30 crore for regular maintenance CAPEX
  • FY26 CAPEX is expected to be around ₹40 crore primarily for maintenance.
  • Strategic investments include:
  • - Expansion of Ankleshwar unit capacity to 442 KL in three blocks, fully operational over three years.
  • - Electrolyte additive capacity build-up following long-term contracts.
  • - Careful evaluation and cautious investment in EV-related projects due to deferrals in the EV market.
  • - Potential joint venture with Enchem under discussion, status quo currently.
  • ₹88 crore from QIP reserved for general corporate purposes and future opportunities.

Track Acutaas Chemical — get its next earnings analysis in your feed

How does Acutaas Chemical rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAcutaas Chemical
Rev 2Mar 1

How does Acutaas Chemical rank in Pharmaceuticals & Biotechnology?

Compare Acutaas Chemical against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →